Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Publication | Open Access

DOI Full Paper Access

2.2K

Citations

References

2017

Year

Yoon‐Koo Kang, Narikazu Boku, Taroh Satoh, Min‐Hee Ryu, Yee Chao, Ken Kato, Hyun Cheol Chung, Jen‐Shi Chen, Kei Muro, Won Ki Kang,

The Lancet

Esophageal CancerGastrointestinal OncologyLeast TwoMedicineGastroenterologyPrevious Chemotherapy RegimensSurgeryPharmacotherapyAdvanced GastricCancer TreatmentOncology